Patents by Inventor IMMUNEX CORPORATION

IMMUNEX CORPORATION has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TWEAK RECEPTOR
    Publication number: 20130224189
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: March 1, 2013
    Publication date: August 29, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: IMMUNEX CORPORATION
  • RANK LIGAND POLYPEPTIDES
    Publication number: 20130203682
    Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.
    Type: Application
    Filed: February 12, 2013
    Publication date: August 8, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: Immunex Corporation
  • SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20130164287
    Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 27, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: Immunex Corporation
  • METHOD OF INHIBITING OSTEOCLAST ACTIVITY
    Publication number: 20130101585
    Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
    Type: Application
    Filed: December 17, 2012
    Publication date: April 25, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: Immunex Corporation
  • TWEAK RECEPTOR
    Publication number: 20130095549
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: December 19, 2012
    Publication date: April 18, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: IMMUNEX CORPORATION
  • B7L-1 POLYNUCLEOTIDES
    Publication number: 20130084603
    Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 4, 2013
    Applicant: IMMUNEX CORPORATION
    Inventor: IMMUNEX CORPORATION